Primary Care Rx Market Offers Second-Rate Return On Investment – Bristol
Pharmaceutical companies marketing primary care products are unlikely to see a significant return on their investment, Bristol-Myers Squibb CFO Andrew Bonfield declared June 10
You may also be interested in...
Roche has the third largest pipeline of new molecular entities in development in the drug industry, the company maintained during an R&D day in New York City May 6
Merck's co-development agreement for Bristol Myers-Squibb's Phase III muraglitazar gives the company a second chance to market a dual PPAR agonist
Bristol-Myers Squibb is reexamining the role of sales forces to find new ideas for reaching physicians